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Introduction 
Lung cancer is the second most common malignant disease (following non-melanoma skin 
cancer) and it has the highest cancer-related mortality. There was an increase of 51% in the 
number of newly discovered cases of lung cancer between 1985 and 2011 (the number of cases in 
males increased by 44% while the increase in women was 76%). Each year 1350000 new cases of 
the disease are detected worldwide. In Hungary, 5189 new cases were registered (52.5/%000) in 
2014 according to data from the pulmonary treatment centers, however, according to the national 
cancer registry the incidence of lung cancer was 11646, while the prevalence was 21226 (215 
%000). Non-small cell lung cancer (NSCLC) accounts for 85-90% of lung cancer cases. Within 
the cases of non-small cell lung cancer, the number of cases of adenocarcinoma has increased on 
a global scale in the past 10 years and its proportion reaches 50% in Hungary. 
 
Change in the therapeutic regimeen in NSCLC 
Only a quarter of cases of NSCLC are detected at a resectable stage. At the time of diagnosis, 
60% of patients have locally advanced (stage IIIB) or metastatic (stage IV) cancer. A systemic 
treatment must be offered to each patient with an ECOG performance status of 0-2 and stage IIIB 
or IV cancer (evidence IA). In the treatment of advanced non-small cell lung cancer histology, 
molecular pathology results, age, performance status, co-morbidities and the patient’s preferences 
have to be taken into consideration. The offered treatment plan must be discussed by a tumor 
board. 
Platinum-based doublet chemotherapy prolongs patients’ life and improves the quality of life in 
the case of performance statuses 0-2. Third-generation cytotoxic medications combined with 
platinum can only provide an average survival of less than 1 year. Recently there has been a 
major paradigm shift in the treatment of NSCLC with the discovery of activating (‘driver’) 
mutations. The term ‘theranostic’, which combines therapy and diagnostics to provide 
individualized treatment, is spreading. 
 
 
 
 
 
 
 
Oncogenic ‘driver’ mutations 
Oncogenic ‘driver’ mutations are known to be present in approximately 60% of cases of 
adenocarcinoma. Mutations of receptors or protein kinases can stimulate signal transduction 
cascades, resulting in an uncontrolled growth, proliferation and survival of tumor cells. 
EGFR 
The most promising predictive factor of NSCLC is epidermal growth factor receptor (EGFR) 
located at position 12 on the short (p) arm of chromosome 7. When EGF binds to EGFR, 
dimerization and autophosphorylation occur and the receptor activates several pathways, leading 
to cell proliferation, development of metastases and migration, in addition to the inhibition of 
apoptosis. First-generation EGFR TKIs including erlotinib and gefitinib target the catalytic 
domain of EGFR through competition of adenosine triphosphatase.  
The first studies on EGFR TKIs tried to relate the efficacy of the medications to the 
overexpression of EGFR. The BR 21 clinical study demonstrated the efficacy of erlotinib in the 
entire, unselected patient population. Erlotinib was registered as a second- and third-line 
treatment of NSCLC based on the results of the BR 21 trial in 2005. A study by Lynch TJ. et al. 
made a breakthrough in the assessment of the efficacy of EGFR TKIs in 2009. Certain mutations 
of the tyrosine kinase domain (exon 19 and 21 deletions) were proven to predict the efficacy of 
erlotinib/gefinitib in this study. These so-called activating mutations have more frequently been 
detected in adenocarcinoma in a certain phenotype – it is present in 50% of the never smoker 
Asian women - than in other populations. Approximately 90-95% of mutations are either small 
deletions on exon 19 (codons 746 -750) or arginine substituting leucine at position 858 of exon 
21 (L858R). A further 3% of them are substitutions of monoacid variations on codon 719 of exon 
18 (G719X) at the position of glycine and 3% are frame insertions on exon 20. The dominant 
oncogenic role of EGFR is supported by the fact that its occurrence and that of other oncogenic 
mutations (such as KRAS, ALK or BRAF) are mutually exclusive. The mutant EGFR has a lower 
ATP-binding capacity than the wild-type, therefore a lower concentration of it is required for 
inhibition. The most important paradigm shift of the previous 10 years in the treatment of 
NSCLC was the administration of EGFR TKIs as a first-line therapy in the case of EGFR 
activating mutations. The first breakthrough was the administration of gefitinib in patients of a 
Far East origin, subsequently in the EURTAC study dominantly Spanish and French patients 
 
 
carrying the EGFR mutation were treated with similar results. The prevalence of the classic 
EGFR mutation was 15% among Spanish patients.  
 
KRAS 
KRAS mutation develops as a consequence of smoking and primarily occurs in adenocarcinoma. 
The presence of KRAS mutations seems to be mutually exclusive with EGFR mutations, is 
associated with the absence of response to EGFR TKIs and has been linked to a reduced 
sensitivity to chemotherapy in more and more studies. Based on the results of the BR 21 trial, 
erlotinib has become an approved medication in Hungary for KRAS mutation negative (wild-
type) locally advanced or metastatic lung adenocarcinomas after failure of at least one prior 
chemotherapy regimeen. As a result, launching an observational cohort study, MOTIVATE, 
conducted to prospectively collect efficacy data on erlotinib administered to patients with the 
wild-type KRAS in routine clinical practice, was possible from 2008. The predictive role of 
classic EGFR mutations has been known since 2009, therefore subsequent determination of 
EGFR mutations from the tumor samples of 100 patients was carried out. 
 
Tumor angiogenesis as a therapeutic target 
It is essential for tumor growth that above a certain size, the tumor forms its own vascular 
network by activating and stimulating the migration of the endothelial cells of the host. One of 
the most important signal transduction pathways of tumor angiogenesis is determined by the 
vascular endothelial growth factor (VEGF) family and its receptors. Inhibiting tumor 
angiogenesis by medication has yielded major advances in the treatment of several types of solid 
tumors, most of our knowledge being related to the administration of bevacizumab (Avastin). In 
lung adenocarcinoma, administration of cytotoxic chemotherapy must be considered if an 
activating mutation cannot be detected. Bevacizumab administered in addition to a combination 
of carboplatin and paclitaxel has been shown to improve overall survival (OS) in patients with a 
performance status of 0 or 1 in a randomized clinical trial. Bevacizumab treatment was continued 
in patients exhibiting no progression following 4-6 cycles of chemotherapy until disease 
progression or the occurrence of unacceptable adverse events. Maintenance treatment with 
Avastin delayed progression of the disease and provided longer OS than induction therapy alone. 
 
 
Bevacizumab combined with cisplatin/gemcitabine has been proved to increase objective 
response rate (ORR) and PFS compared with a treatment without bevacizumab in another phase 3 
trial, however, no improvement in OS has been shown (AVAIL trial). ESMO and national 
guidelines recommend chemotherapy to patients with a performance status of 0 or 1 in 
KRAS/EGFR double wild-type adenocarcinomas. In the case of angiogenesis inhibitor therapy,  
no biomarker was found which could help to select the therapeutic option. Due to the 
controversial data we have launched several national multicenter studies (AVALANCHE, 
AVAMAIN) involving a real patient population with several co-morbidities. In addition to 
providing data on PFS and OS, these studies are expected to reveal the characteristics of patients 
eligible for maintenance bevacizumab treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives 
a) Determination of the efficacy of erlotinib as a second- or third-line treatment in IIIB or IV-
stage lung adenocarcinoma patients screened for KRAS mutation. 
b) Investigation of the efficacy and adverse events of EGFR TKI administered as a second- or 
third-line treatment in advanced and metastatic lung adenocarcinoma. 
c) Analysis of the prevalence of classic EGFR mutations in clinical practice. Assessment of 
the efficacy of EGFR TKIs in cases of lung adenocarcinoma positive for EGFR activating 
mutation. 
d) Investigation of the efficacy of induction and maintenance therapy with bevacizumab in 
advanced and metastatic lung adenocarcinoma in relation to KRAS mutation status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient population, methods and results 
Efficacy of erlotinib as a second- or third-line treatment in IIIB or IV-stage lung 
adenocarcinoma patients screened for KRAS mutation 
MOTIVATE is an open-label, non-randomized, multicenter, non-interventional trial of erlotinib 
monotherapy investigating the efficacy of erlotinib in routine clinical practice in Hungary. In 
each case codon mutations 12 and 13 of exon 2 of the KRAS gene were analysed in the 
histological or cytological samples at the pathological departments of the centers prior to 
enrollment. Study population included patients with advanced (stage IIIB/IV) KRAS mutation-
negative lung adenocarcinoma previously treated with one or two lines of standard systemic 
chemotherapy. The primary endpoint was PFS, while secondary endpoints were OS and best 
tumor response. The protocol was approved by the local ethical committee (No: 882-0/2010-
1018EKU). Patients were administered erlotinib 150 mg/day orally until disease progression or 
the development of unacceptable adverse events. Response grading was evaluated by two 
independent radiological expert investigators using CT, MRI, X-ray or US in every two months. 
Dose modification of erlotinib and administration of supplementary medication were based on 
the clinical practice and the discretion of investigators.  
Investigation of EGFR mutation: 4 EGFR exons (18, 19, 20, 21) were analysed retrospectively in 
the tumor samples of 100 patients. PCR amplification and sequencing of the EGFR gene were 
performed with the Roche 454 FLX sequencing instrument. 47 different tumor mutations were 
found in 35 of the 100 tumor samples. 16 tumors contained the classic mutations: exon 19 was 
detected in 9 cases, exon 21 L858R in 5 cases, exon 21 L861Q in 1 case and exon 18 4G717A in 
1 case. 18 tumors contained only rare mutations, the clinical significance of which is largely  
unkown.  
Statistical analysis: Descriptive statistical methods were used for analyzing efficacy data. Kaplan-
Meier curves were generated to display PFS and OS. Differences between groups were calculated 
with a Log Rank test. PFS was defined as the time from the start of administration of erlotinib to 
the first documented progression or death. Table 1 summarizes the demographic and clinical data 
of patients enrolled to the prospective study.  
 
 
 
 
Table 1.Demographic and clinical data in the MOTIVATE study 
Patient characteristics  n (%) 
Total number of patients  327 
Age Median 60.8 years 
Gender Male 164 (50.2) 
Female 163 (49.8) 
Ethnic origin Caucasian 327 (100.0) 
ECOG PS 0 118 (36.1) 
1 169 (51.7) 
2 36 (11.0) 
3 4 (1.2) 
Stage IIIB 101 (30.9) 
IV 226 (69.1) 
Therapeutic line Erlotinib second-line 214 (65.4) 
Erlotinib third-line 113 (34.6) 
Smoking status Never smoker 104 (31.8) 
Former smoker 128 (39.1) 
Current smoker 95 (29.1) 
 
Median PFS was 3.3 months (95% CI 2.93-3.67) and median OS was 14.4 months (95% CI 9.46-
19.34). Median PFS and OS were significantly longer in females when compared to males (3.8 
vs. 3.2 months;p< 0.01 and 20.5 vs. 9.4 months; p = 0.042, respectively). Median OS was not 
significantly longer in patients receiving erlotinib second-line versus those who received erlotinib 
third-line (16.1 months vs. 9.3 months; p = 0.631). No difference was observed in OS when 
stratified to disease stage (IIIB vs. IV) or smoking status (current smoker, never smoker, former 
smoker). It should be noted, however, that in the third-line treated group never-smoker patients 
lived twice as long as current smokers (11 vs. 5.5 months), which was a significant difference (p 
= 0.039). A significant and clinically meaningful correlation was observed between ECOG PS 
status and survival. The longest median OS (20.5 months) was observed in patients with ECOG 
PS 0-1 receiving erlotinib in second-line, and in asymptomatic ECOG PS 0 patients (25.7 
months), irrespective of the line of treatment (Fig. 1.). 
 
 
 
Figure 1. Overall survival of lung adenocarcinoma patients treated with erlotinib according 
to therapeutic line and performance status 
 
The correlation of PFS and OS with demographic and clinical factors is summarized in Table 
2. Male gender and poor ECOG status had a detrimental effect on therapeutic response. 
Table 2. PFS and OS according to different baseline characteristics 
Characteristic  PFS (months) (95% 
CI)) 
p value OS (months) (95% 
CI)) 
p value 
Gender Male 3.2 (2.99-3.41) <0.01 9.4 (6.29-12.45) 0.02 
Female 3,8 (2,85-4,75) 20,5 (10,36-30,71) 
Stage IIIB 3.5 (2.75-4.19) 0.697 15.6 (9.70-2.57) 0.063 
IV 3.2 (2.72-3.74) 11.0 (5.48-16.46) 
Smoking 
status 
Never 
smoker 
3.5 (1.78-5.28) 0.467 15.2 (6.12-24.28) 0.085 
Former 
smoker 
3.2 (2.89-3.58) 11.9 (4.79-19.02) 
Current 
smoker 
3.3 (2.73-3.87) 10.9 (3.28-18.52) 
ECOG PS 0 4.8 (2.96-6.57) <0.001 25.7 (16.28-35.12) <0.001 
1 3.1 (2.79-3.34) 10.9 (5.4-16.40) 
2 2.1 (0.96-3.18) 2.5 (1.85-3.15) 
3 1.7 (NA) 1.9 (1.61-2.25) 
 
 
 
The correlation of median PFS and OS with the results of EGFR mutation analysis is summarized 
in Table 3. 
Table 3.The correlation of median PFS and OS with the results of EGFR mutation analysis 
EGFR gene mutation status PFS (months) pvalue OS (months) pvalue 
EGFR wild-type n=65 2.9   7.2   
Classic EGFR mutation n=16 13.2 p<0.001 29.0 p<0.001 
Rare EGFR mutation n=18 3.0 p=0.432 5.2 p=0.68 
 
The PFS and OS of patients positive for the classic EGFR mutation were significantly longer 
compared with those carrying the EGFR wild-type and rare mutations. 
Best response data were available in the case of 252 patients. Complete response (CR) was found 
in 3 patients (1.2%), partial response was detected in 51 patients (20.2%) and stable disease (SD) 
was found in 123 patients (48.8%) as best response, all together resulting in a disease control rate 
of 70.2%. 75 patients (29.8%) progressed despite erlonitib treatment.  
Dose modification was necessary for 48 patients, mainly due to skin lesions and diarrhea. Dose 
reduction due to skin lesions was required in 11% of the patients, while diarrhoea was 
responsible for the modification in 4.3% of the cases. A statistically longer PFS was detected in 
patients requiring dose modification due to adverse events (8.5 months vs. 3.1 months; p<0.001). 
 
The occurrence of classic EGFR mutations in our clinical practice  
The efficacy of EGFR TKIs in cases of EGFR activating mutation positive lung 
adenocarcinoma 
In the past 6 years (Jan 2009 - Aug 2015), 446 patients with lung adenocarcinoma were screened 
for EGFR mutations and EGFR activating mutation was found in 44 cases (9.86%). The EGFR 
analysis was performed on both cytology samples (pleural fluid, bronchial brush biopsy, 
transbronchial needle aspiration and transthoracic aspiration specimens) and formalin fixed 
paraffin-embedded tissue blocks. Following DNA extraction, exon 19 and exon 21 of EGFR were 
amplified with polymerase chain reaction. The PCR conditions were set as described by Asano et 
al. The mutated (deleted) and wild-type exon 19 products were separated by fragment length 
analysis. Following purification, the PCR product was Sanger sequenced using the exon 21 
 
 
primers to detect point mutations. An expert pathologist evaluated the tumor cell ratio and the 
sample was rejected for EGFR testing below a ratio of 30%.  
Data of these patients were analysed retrospectively with respect to gender, smoking status, type 
of EGFR mutation and EGFR TKI treatment. In patients receiving EGFR TKI treatment, disease 
control rate (DCR), PFS, primary resistence and radiological progression were also determined. 
Statistical analysis was performed using the IBM SPSS Statistics Version 22.0 (SPSS, Inc., 
Chigaco, IL, USA). Kolmogorov- Smirnov test was used to determine the distribution of the data. 
Normally distributed data were presented as mean ± SE. Relationships between bimodal variables 
were analysed with Chi-square and Fischer's exact test. DCR, 6-month and 12-month PFS were 
investigated with binary logistic regression analysis. Results with p values <0.05 were considered 
significant.   
The average age of the patients with EGFR-mutated lung adenocarcinoma was 69.6 ± 1.6 (40-89) 
years, while the female/male ratio was 31/13. Males were significantly younger than women 
(62.9 ± 24.4 versus 72.1 ± 2.0 years; p= 0.008). Never smokers accounted for 77.2% of the 
patient population, 4 patients were former smokers and 6 patients were smokers at the time of 
diagnosis. Focusing on EGFR mutations, exon 19 deletion was detected in 61.4 % of the patients, 
while L858R point mutation in exon 21 was observed in 34.1 % of them. In one case both exon 
19 and 21 mutations were detected simultaneously. A rare mutation located in exon 21 was found 
in another patient. Until the end of the observation period, 38 patients received EGFR TKI 
treatment: 29 patients were treated with erlotinib and nine received gefitinib. TKI treatment was 
started as 1st, 2nd and 3rd line treatment in 22, 11 and 5 cases, respectively. The efficacy of TKI 
treatment was first evaluated after 2 months of therapy. Data were available in 35 cases, because 
3 patients died within two months after starting the treatment. Primary resistence to TKI was 
determined if disease progression was detected at the 2-month visit; it occurred in 5 cases. The 
beneficial effect of TKI treatment was found in 30 patients, with a disease control rate of 85.7%. 
One patient responded with complete remission, while partial response and stable disease were 
detected in 16 and 13 cases, respectively. No difference was found between groups of patients 
responding with complete or partial remission and stable disease with respect to age, gender, 
mutation type, smoking status and TKI therapy. The progression free survival of the 35 patients 
was 12.4 ± 2.1 months, the longest PFS being 54 months and this patients is still on TKI 
treatment. At the time of closing the database, 6 patients received TKIs for less than 6 months, 21 
 
 
patients exhibited PFS over 6 months (72.4%) and 11 out of 22 patients survived without 
progression over 12 months (50%).  
PFS over 6 months was significantly more common in never smokers compared to current 
smokers and former smokers (p=0.005); age, gender, and the type of mutation did not impact on 
the efficacy of TKI treatment and the duration of PFS. The independent determinants of 
therapeutic response are depicted in regression models (Table 4). Age, gender, type of mutation, 
smoking status and the sequence and type of TKI therapy were included in these analyses. The 
sequence of TKI therapy was an independent determinant of therapeutic response (p=0.046); 
DCR was higher in patients treated in first line (94.7%) than in those treated in second or third 
line (81.8% and 60.0%). The detrimental effect of smoking and former smoking was confirmed at 
the 12-month PFS. 
  
 
 
Table 4. Independent determinants of therapeutic response to EGFR TKI therapy in lung 
adenocarcinoma patients with mutated EGFR - binary linear logistic regression models 
 Variables Independent 
determinants 
p 
value 
Cox & 
Snell R2 
Nagelker-ke 
R2 
DCR Age 
Gender 
Non-smoking 
Type of EGFR mutation 
Sequence of TKI therapy 
Type of TKI 
Sequence of TKI 
therapy 
0.045 0.100 0.179 
12-month 
PFS 
Age 
Gender 
Non-smoking 
Type of EGFR mutation 
Sequence of TKI therapy 
Type of TKI 
Non-smoking 
Type of TKI 
0.052 
0.014 
0.359 0.478 
 
AVALANCHE prospective multicenter study 
With regard to the results of pivotal clinical studies, we found it worthwhile to investigate the 
efficacy of platinum-based chemotherapy/bevacizumab combinations in Hungarian patients in a 
postmarketing observational study.  
In the AVALANCHE study the efficacy of simultaneous administration of bevacizumab and a 
combination of third-generation cytotoxic agents and platinum was investigated in Hungarian 
clinical practice. The observational study was carried out at 28 sites and the period of enrollment 
lasted from June, 2008 to April, 2011. IIIB/IV-stage lung adenocarcinoma patients received a 
total of 6 cycles of a combination of platinum-based doublet chemotherapy and bevacizumab (7.5 
mg/ body weight in kilograms). Patients without progression received maintenance treatment 
with bevacizumab until the occurrence of progression or unacceptable toxicity. PFS was the 
primary endpoint and OS and DCR were the secondary endpoints. Patients were also analysed 
regarding whether they exhibited progression or not during the initial therapy, i.e. whether they 
received maintenance therapy with bevacizumab or not. The groups were compared with a log 
rank method.  
283 IIIB/IV-stage lung adenocarcinoma patients were enrolled to the study. Patient 
characteristics: average age was 58.2 (18-78) years, 55.5% of them were male, 18.4% were in 
IIIB stage, 79.9% were in IV stage, the adenocarcinoma/other ratio was 95:8/4.2 % and ECOG 
 
 
performance statuses were 0:30.8%, I: 59.7%, II:2.6% and ≥ III:1.4%, respectively. 43% of the 
patients received maintenance treatment with bevacizumab in addition to induction treatment. 
Median PFS was 7.2 months and OS of the entire cohort was 15.2 months. Patients receiving 
maintenance treatment with bevacizumab had longer PFS and OS as well (Table 5).  
Table 5. Median PFS and OS in the AVALANCHE study in relation to maintenance of 
Avastin treatment 
 
 
Without maintenance of 
Avastin 
With 
maintainedAvastin 
Log Rank p value 
Median PFS 
(months) 
5.8 9.1 <0.001 
Median OS (months) 10.2 26.2 <00001 
 
Best responses of patients enrolled to the study were: CR/PR/SD/PD: 1.5/29.9/26.9/9.1%. 
Platinum-based doublet/bevacizumab in first-line in IIIB/IV-stage adenocarcinoma patients 
 
At the 1st Department of Medicine, University of Pécs, Clinical Center, data of 174 IIIB/IV-stage 
lung adenocarcinoma patients having received first-line bevacizumab treatment combined with 
chemotherapy between 2 May, 2012 and 26 July, 2015 were analyzed. To determine the efficacy 
of the therapy, PFS and OS data of all patients receiving bevacizumab treatment were 
investigated. PFS and OS data were evaluated stratified to KRAS mutation status. PFS and OS 
values of patients having received maintenance treatment with bevacizumab and those of patients 
not enrolled to the maintenance phase were compared. All patients had an ECOG PS of 0 or 1 
and 69 of them were administered combination treatment with bevacizumab. Sufficient data on 
PFS were available in 61 cases and in 58 cases there were data available to calculate the survival 
too.  
Therapeutic regimees applied: CBP-Paclitaxel-Avastin:    74.0% (51/69) 
CBP-Docetaxel-Avastin:    20.3% (14/69) 
Cisplatin-Docetaxel-Avastin:   2.9% (2/69) 
CBP-Gemcitabine-Avastin:    1.4% (1/69) 
Cisplatin-Gemcitabine-Avastin:   1.4% (1/69) 
 
 
 
Forms of Avastin treastment:               Administered only in the induction phase:  44.9% (31/69) 
Administered in the maintenance phase too: 55.1% (38/69)
        
 
The average age of the patients was 60.93 years and 53.6% of patients included in the 
retrospective study were male and 46.4% were female. Prior to the therapeutic decision KRAS 
mutation status was determined for all patients. 36.8% of the patients were positive for KRAS 
mutation. The estimated PFS and OS values are summarized in Table 6 stratified to KRAS 
mutation status and maintenance of Avastin treatment.  
Table 6. Estimated average and median PFS and OS stratified to KRAS mutation status and 
maintenance of Avastin treatment 
 estimated PFS estimated OS 
 average median p value average median p value 
total 11.8 6.0  20.2 14.0  
KRAS wild 12.8 7.0 
0.387 
22.5 16.0 
0.169 
KRAS-mutated 7.4 4.0 10.7 11.0 
receiving maintained Avastin 
treatment 
17.4 12.0 
<0.001 
27.9 21.0 
<0.001 
not receiving maintained Avastin 
treatment 
3.8 3.0 9.3 7.0 
 
KRAS mutation status did not impact on progression-free survival and survival, however, PFS 
and survival of patients receiving maintenance treatment with bevacizumab were significantly 
better (Figure 2). 
 
 
 
Figure 2. Survival of lung adenocarcinoma patients having received maintenance 
treatment with bevacizumab following platinum-based doublet bevacizumab induction 
treatment with regard to maintenance treatment with bevacizumab (N=69)  
 
 
Discussion 
Erlotinib was proved to be more effective with regard to PFS and OS compared to placebo in a 
retrospective analysis of subgroups of NSCLC patients carrying the wild-type EGFR in the BR 
21 and SATURN studies in 2013. The results of MOTIVATE, a multicenter study launched in 
Hungary in 2008, confirmed the efficacy of erlotinib treatment administered in second and third 
line in lung adenocarcinoma patients carrying the KRAS wild-type in Hungarian routine clinical 
practice.   
The longest survival (20.5 months) was detected in ECOG PS 0-1 patients screened for KRAS 
mutation receiving second-line erlotinib treatment. This finding draws the attention to the 
importance of assessing patients' performance statuses objectively. In patients carrying wild-type 
KRAS, long survival was found with a relatively low remission rate and, simultaneously, almost 
50% of stable disease control. This result confirms the fact that the increased ability of tumor 
cells to multiply is in the background of tumorgenesis in EGFR wild-type tumors. This 
mechanism is inhibited by erlotinib, resulting in the stabilization of disease. Survival data of 100 
patients analyzed retrospectively for EGFR (exons 18-21) mutation indicated that patients 
carrying the classic 19, 21 mutations had considerably longer PFS and OS values than those 
carrying rare mutations. 
At our Division of pulmonology, the frequency of EGFR mutation is 9.86%, which is lower than 
it was previously published for Caucasian populations. The distribution of mutations was similar 
to literature data. TKI treatment of these patients is promising, since 85% of the patients 
benefited from TKI therapy. First-line treatment seems to be the best therapeutic option, which 
highlights the importance of early evaluation of EGFR status to determine first-line treatment.  
Randomized, phase 3 clinical trials demonstrated that never smokers with EGFR mutated 
adenocarcinoma had the largest benefit from TKI treatment. Our retrospective analysis also 
revealed that none of the patients who were positive for EGFR mutation and were smokers at the 
time of the diagnosis had PFS over 6 months. PFS over 6 and 12 months was detected in 72.4% 
and 50 % of patients, respectively, irrespective of age, gender and type of mutation. It is 
important to note that male gender was not associated with disadvantages in our patient 
population. 20% of the patients required dose reduction due to adverse events.  
 
 
The other new therapeutic approach is inhibition of tumor angiogenesis combined with 
chemotherapy to improve therapeutic response of lung adenocarcinoma patients. In the two 
pivotal clinical trials, 66% of the patients completed chemotherapy without progression and were 
administered maintenance treatment with Avastin. PFS and OS values of patients receiving 
maintenance treatment with bevacizumab were higher than those of patients not receiving 
maintenance therapy. In the national AVALANCHE study, 40% of the patient population 
received maintained Avastin treatment following induction treatment. Patients receiving 
maintenance treatment had a 2.5-times longer survival than patients not receiving maintenance 
treatment. It can be established that fewer patients reached the maintenance phase, however, 
these patients had a considerably long survival. Our own retrospective clinical study also 
confirmed that patients receiving maintenance Avastin treatment exhibit a 3-times longer overall 
survival compared to those who are enrolled only to the induction phase (21 vs. 7 months). 
Comparing international and available Hungarian data, which show an occurrence of 25-29.55% 
for KRAS mutations, our study detected a higher occurrence rate of 36.8% for KRAS mutations. 
International data support that KRAS codon mutations 12 and 13 had a negative predictive value 
with regard to platinum-based therapy. In our study KRAS mutation status did not have a 
significant impact on PFS and OS values given in response to platinum doublet bevacizumab 
combination therapy, although such a tendency was detectable, the difference did not prove to be 
significant, probably due to the small number of cases.  
  
 
 
Summary of novel results 
1. A lower number of lung adenocarcinoma patients positive for the classic EGFR mutations 
were diagnosed in the oncopulmonological center of the University of Pécs compared to 
available European data. The proportion of patients positive for EGFR mutations 19 and 
21 was similar to that found in the database of the National Korányi Institute. The number 
of patients carrying the KRAS mutation was higher in our population.  
2. EGFR TKI treatment had the best disease control when administered in first line. This 
result highlights the importance of determining KRAS mutation status prior to the start of 
the therapy. The treatment provided a progression-free survival of longer than 6 months in 
never smokers. Male gender was not associated with disadvantages with regard to TKI 
treatment.  
3. Erlotinib treatment administered in second and third line taking KRAS negativity as a 
selection criterion proved to be considerably effective in adenocarcinoma patients 
carrying the wild-type KRAS in MOTIVATE, a national prospective, multicenter study.  
4. A retrospective analysis in MOTIVATE study has also shown that patients with wild-type 
KRAS exhibited the best survival when they were carrying the classic EGFR mutation. 
Patients with the double wild-type of adenocarcinoma had a shorter survival. 
5. AVALANCHE national multicenter prospective study showed a longer OS in patients 
receiving maintenance of Avastin treatment compared to those enrolled to the clinical 
studies.  
6. In our retrospective studies, patients received maintained Avastin treatment in a high 
proportion owing to proper selection of patients. Patients receiving maintenance of 
Avastin treatment had significantly longer PFS and OS than those not receiving 
maintenance treatment. In our routine clinical practice we had similar PFS and OS values 
to those detected in clinical studies.  
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